BioAtla raises $9.2M in registered direct offering to fund mid-stage TCE and ADC programs

BioAtla, Inc.

Sold 9,679,158 shares and accompanying warrants at $0.9520/unit; gross proceeds ~$9.2M.
Warrants exercisable at $1.19/share for 5.5 years, beginning 6 months after issuance.
Proceeds to fund BA3182 Phase 1 dose escalation data (2Q25) and Phase 2 expansion data (1H26).
Proceeds also to fund mecbotamab vedotin Phase 2B data in mKRAS NSCLC (1H26).
Officers and directors subject to 75-day lock-up; company restricted on equity issuance for 75 days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.